[{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Marinomed Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Marinomed Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Marinomed Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Marinomed Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Marinomed Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Marinomed Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Luoxin Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRIA","productType":"Steroid","year":"2021","type":"Licensing Agreement","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Marinomed Biotech","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Spray","sponsorNew":"Marinomed Biotech \/ Luoxin Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Marinomed Biotech \/ Luoxin Pharmaceutical"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Carrageenan","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Marinomed Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Marinomed Biotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Marinomed Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Carrageenan","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Marinomed Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Marinomed Biotech \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Marinomed Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Carrageenan","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Marinomed Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Marinomed Biotech \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Marinomed Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Austrian Research Promotion Agency","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Carbohydrate","year":"2020","type":"Funding","leadProduct":"Carragelose","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Marinomed Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Marinomed Biotech \/ Austrian Research Promotion Agency","highestDevelopmentStatusID":"1","companyTruncated":"Marinomed Biotech \/ Austrian Research Promotion Agency"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Marinomed Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Marinomed Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Marinomed Biotech \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Marinomed Biotech

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Under the terms of the agreement, Shandong Luoxin will gain the exclusive rights for the development, manufacture, and commercialization of Budesolv® (Budesonide Nasal spray) in China (including Chinese mainland, Hong Kong and Macao SAR, Taiwan region).

                          Product Name : Budesolv

                          Product Type : Steroid

                          Upfront Cash : $2.0 million

                          October 19, 2021

                          Lead Product(s) : Budesonide

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Luoxin Pharmaceutical

                          Deal Size : $22.0 million

                          Deal Type : Licensing Agreement

                          blank

                          02

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Tacrosolv is an improved formulation of tacrolimus, an immunomodulator that can suppress inflammatory reactions, including allergic symptoms. Tacrosolv promises higher bioavailability for local treatment of ocular inflammation.

                          Product Name : Tacrosolv

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          April 12, 2021

                          Lead Product(s) : Tacrolimus

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : The ongoing randomized, placebo controlled, crossover, double-blind, single site Phase II clinical trial is testing Tacrosolv, an improved formulation of tacrolimus, in adult subjects who are suffering from grass pollen induced allergic rhinoconjunctivit...

                          Product Name : Tacrosolv

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          March 11, 2021

                          Lead Product(s) : Tacrolimus

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Carragelose is a sulfated polymer from red seaweed and a unique, broadly active anti-viral compound. It is known as a gentle yet effective and safe prevention and treatment against respiratory infections.

                          Product Name : Carragelose

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 20, 2020

                          Lead Product(s) : Carrageenan

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : This drug candidate is currently being evaluated in phase II clinical studies for the treatment of Conjunctivitis, Allergic.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 31, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Data from Marinomed’s cell-culture study confirm that Carragelose® works in a dose-dependent manner to strongly reduce the infection of cells from the SARS-CoV-2 virus.

                          Product Name : Carragelose

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 16, 2020

                          Lead Product(s) : Carrageenan

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Marinomed Biotech's new marketing partner Fidia Farmaceutici Spa is set to offer Carragelose®-based nasal sprays on the Italian market as of autumn 2020.

                          Product Name : Carragelose

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 02, 2020

                          Lead Product(s) : Carrageenan

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Funding is directed towards a trial which will clinically test an inhalation solution with Carragelose® as an acute treatment for viral pneumonia caused by SARS-CoV-2 or other respiratory viruses.

                          Product Name : Undisclosed

                          Product Type : Carbohydrate

                          Upfront Cash : Undisclosed

                          April 28, 2020

                          Lead Product(s) : Carragelose

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Austrian Research Promotion Agency

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank

                          09

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Budesolv (Budesonide) is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Rhinitis, Allergic.

                          Product Name : Budesolv

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          November 28, 2018

                          Lead Product(s) : Budesonide

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : IPD1 CD19 eCAR T cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, B-Cell.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          July 05, 2017

                          Lead Product(s) : iPD1 CD19 eCAR T cell

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Peking University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank